Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 85 pages | ID: RF8673B747B0EN
Global Markets Direct

Abstracts

Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Drugs In Development, 2022, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 11 and 13 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Rosacea - Overview
Rosacea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rosacea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rosacea - Companies Involved in Therapeutics Development
Rosacea - Drug Profiles
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Jun 13, 2022: Dermata announces final patient enrolled in a phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea
Mar 17, 2022: Journey Medical Corporation announces first patient dosed in phase 3 clinical trial evaluating DFD-29 (minocycline modified release capsules 40 mg) for the treatment of rosacea
Nov 17, 2021: Dermata announces first patient enrolled in its phase 2 trial of DMT310 for the treatment of moderate-to-severe rosacea
Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
Oct 12, 2018: BioPharmX enrols first subject in Phase llb trial of BPX-04
Aug 01, 2018: BioPharmX secures IRB approval to start Phase ll trial of BPX-04
May 24, 2018: BioPharmX Studies Show Hydrophilic Topical Minocycline Gel May Be the Preferred Treatment Option for Rosacea Patients
Mar 20, 2018: U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug BPX-04
Jan 26, 2018: BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin
Jan 12, 2018: BioPharmX to Present BPX-04 Rosacea Data at Two Leading Clinical Conferences This Month
Dec 13, 2017: Hovione Announces Enrollment of First Patient in MARS, a Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Sep 12, 2017: BioPharmX Announces Preliminary Data from Rosacea Feasibility Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Rosacea, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, 2022
Rosacea - Pipeline by Alfasigma SpA, 2022
Rosacea - Pipeline by Amgen Inc, 2022
Rosacea - Pipeline by Amytrx Therapeutics Inc, 2022
Rosacea - Pipeline by AOBiome LLC, 2022
Rosacea - Pipeline by Arcutis Biotherapeutics Inc, 2022
Rosacea - Pipeline by Attillaps Holdings Inc, 2022
Rosacea - Pipeline by Biomimetix JV LLC, 2022
Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, 2022
Rosacea - Pipeline by Cellix Bio Pvt Ltd, 2022
Rosacea - Pipeline by Dermata Therapeutics Inc, 2022
Rosacea - Pipeline by Evommune Inc, 2022
Rosacea - Pipeline by Hovione FarmaCiencia SA, 2022
Rosacea - Pipeline by Maruho Co Ltd, 2022
Rosacea - Pipeline by Matrisys Bioscience Inc, 2022
Rosacea - Pipeline by NanoPharmaceuticals LLC, 2022
Rosacea - Pipeline by Perpetuum BV, 2022
Rosacea - Pipeline by Promius Pharma LLC, 2022
Rosacea - Pipeline by Retinoids JSC, 2022
Rosacea - Pipeline by Sunny Pharmtech Inc, 2022
Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, 2022
Rosacea - Pipeline by Timber Pharmaceuticals Inc, 2022
Rosacea - Pipeline by TWi Biotechnology Inc, 2022
Rosacea - Pipeline by VYNE Therapeutics Inc, 2022
Rosacea - Dormant Projects, 2022
Rosacea - Dormant Projects, 2022 (Contd..1)
Rosacea - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rosacea, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022